again. The column was then drained and a further 15 mL of solvent 1 was added and drained away. Fifteen milliliters of solvent 1 was added and a 1-cm circle of glass-fiber paper placed atop the Sephadex LH-20 column. Next day, the column was ready for use. Thus the Sephadex was properly and completely equilibrated.
Serum was extracted with dichloromethane (1), the extract was evaporated under nitrogen, and 2000 cpm of purified tritiated testosterone (New England Nuclear, Boston, MA 02118) in 0.1 mL of absolute ethanol (E. Merck, GR grade) was then added to the vial. The ethanol was evaporated and extract and tracer were dissolved in 0.4 mL of solvent 2, which was applied to a column that had just been drained. The column was washed with 40 successive 2-mL applications of solvent 2, each effluent being collected into a scintillation vial. The 40 collections were evaporated under nitrogen, 1 mL of ethanol was added to the residue in each vial, and the contents of the vials were vortex-mixed. We transferred 0.5 mL to assay tubes, and the ethanol in the assay tubes and scintillation vials was evaporated under nitrogen. Scintillation fluid was added to the vials and the radioactivity was counted, to evaluate recovery. The assay tubes were then processed as previously described (1) with the Diagnostic Products Corp. (Los Angeles, CA 90064) radioimmunoassay kit.
The testosterone tracer used to monitor analytical recovery from the column was purified as follows: 5 mL of ethanol was added to the 250-1tCi tracer solution as supplied by the manufacturer, the solutions were mixed, and 0.2 mL was sampled into a scintillation vial and evaporated under nitrogen. We then added 0.4 mL of solvent 2, vortex-mixed, applied the solution to a Sephadex LH-20 column, and collected 2-mL fractions as above. The fractions were evaporated; the residues were each dissolved in 1 mL of ethanol and subsampled, to monitor elution of the tracer. The fraction with the highest count was evaporated, and the residue was dissolved in 0.4 mL of solvent 2 and applied to a fresh column, and 2-mL fractions were collected. These were evaporated, the residues dissolved in 1 mL of ethanol, and subsampled to monitor tracer elution. The fraction from the second chromatography with the highest count was evaporated and the residue was dissolved in ethanol and used for recovery estimations. All columns for the chromatography of the danazol, patients' extracts, or tracer were used only once.
Farmos Diagnostica (SF-20101 Turka 10, Finland) and Bio-RIA (Louisville, KY, 40299) testosterone radioimmunoassay kits were used as recommended by the manufacturers except that both assays were incubated overnight at room 17 testosterone antibodies, and it is eluted in the above chromatographic system just before testosterone. Thus we calculated the plasma testosterone concentrations we found after chromatography by using the 2-mL column fraction with the highest testosterone recovery so as to avoid the preceding dihydrotestosterone and the succeeding danazol fractions. After Sephadex LH-20 chromatography of the serum extracts followed by testosterone radioimmunoassay, the serum testosterone concentrations in women taking danazol (mean 0.7 nmol/L, SD 0.3, n = 7) were slightly (but not significantly) lower than those for normal women (mean 1.3 nmol/L, SD 0.6, n = 3).This isconsistent with the biological action of danazol in suppressing ovarian function (1) . About a third of testosProducts Corp. testosterone radioimmunoassay kit was used as previously described (1).
Danazol (from Winthrop Laboratories, Ermington, Australia, 2115) was used as previously described (1).
Women receiving danazol were taking daily doses of 400-800 mg for treatment of endometriosis. Table 1 shows that the Diagnostic Products Corp. method appears to have been modified since the first investigation. The mean plasma testosterone concentration obtained from August 1980 to May 1981 was about a third that found during the earlier period (July-October 1979). However, the mean for the 1980-1981 period is about fourfold that for normal women (mean 1.9 nmol/L, SD 0.6, n = 21) with use of an extract from 50 iL of serum. Moreover, the assay also stifi shows the non-parallel effect of using extracts from different serum volumes. In both periods in Table 1 , the plasma testosterone concentrations were approximately doubled if we used extracts from 15 pL instead of the usual 50 tL of serum.
Results and Discussion
With the Sephadex LH-20 chromatography, the tritiated testosterone eluted in the 20-to 26-mL fractions. Radioimmunoassay of eluted fractions of patients' extracts applied to a column showed that non-testosterone immunoreactivity (danazol?) was present in the 30-to 42-mL fractions. Radioimmunoassay of eluted fractions after danazol alone was applied to a column showed immunoreactivity in the 30-to 54-mL fractions. These figures apply to chromatography at 23 #{176}C; even small temperatures changes alter these elution positions. The larger elution volumes (fractions 30 to 54 mL) with the danazol compared with the smaller volume (fractions 30 to 42 mL) observed with the serum extracts from women receiving danazol may be due to cross-reacting impurities in the danazol provided by Winthrop Laboratories. Steroids are eliminated from the body by various mechanisms, such as terone and androstenedione (a peripheral precursor of testosterone) is secreted by the ovaries (5), and decreased ovarian function would be expected to result in decreased plasma testosteroneconcentrations.
Mean serum testosterone concentrations as measured with the Farmos Diagnostica radioimmunoassay kit with extraction but without chromatography were significantly greater (p <0.001) in women taking danazol (mean 3.3 nmol/L, SD 0.9, n = 27) than in normal women (mean 2.0 nmol/L, SD 0.6, n = 10). Table 2 shows that the Farmos Diagnostica method has the same non-parallel effect as the Diagnostic Products Corp. method: an extract from 12.5 zL of serum gave 1.4-and 2.0-fold the value for an extract from 50 sL of serum for the Farmos Diagnostica and Diagnostic Products Corp. methods, respectively.
Plasma testosterone concentrations as measured by the Bio-RIA kit without extraction or chromatography in samples from women taking danazol are very high, averaging (Table  3 ) greater than our upper limit of normal for men (10-35 nmol/L). To investigate possible non-parallel effects, we assayed 20 tL as well as the recommended 10 sL of serum from women taking danazol and in male and female patients not taking it. Table 3 shows the data from thisexperiment. We saw no significant difference in the serum testosterone concentration in the two volumes assayed, either for the women taking danazol or for the patients not taking danazol. Serum from four normal men and seven women taking danazol were serially diluted with serum from a woman with a low plasma rect non-extraction method measures danazol and (or) its metabolites in the serum of women taking danazol in a parallel manner. Table 3 shows that for the Bio-RIA method the plasma testosterone concentrations were slightly smaller in women taking danazol if the serum was extracted before radioimmunoassay. This may be because some of the more polar metabolites of danazol do not pass into the dichloromethane extract. Figure 1 shows the structural formulas of testosterone and danazol. Danazol has a ring system attached to the A ring and an alpha group attached to the C17 atom of the testosterone skeleton. The antibodies used in the Diagnostic Products Corp. and Farmos methods were raised against testosterone conjugated to the carrier protein through the C3 atom of the A ring of testosterone. Antibodies generally recognize steroid structures furthest from the site of conjugation of the steroid to the carrier protein (6) . Hence the ring of danazol attached to the A ring is probably poorly recognized by these antibodies. Moreover, the beta surface of the danazol molecule is identical to that of testosterone in the region of the B, C, and D rings.
Perhaps many of the antibody binding sites in these heterogeneous antisera are directed against the beta surface of testosterone. The antibody used in the Bio-RIA method was raised against tsstosterone conjugated to the carrier protein through the C19 carbon atom of testosterone, and it is surprising that such an antibody cannot readily distinguish the two gross stereochemical differences between testosterone and danazol. Testosterone antibodies may tend to give standard curves parallel to danazol when they are raised to testosterone-protein immunogens conjugated through the C19 (but not the C3) atom of testosterone.
All three methods show interference of danazol in the assays. It is important to be aware of this when serum testosterone concentrations are being measured; otherwise, women taking danazol might be thought to have severe disturbances of testosterone metabolism, associated perhaps with testosterone-secreting tumors. The opposite is true: women taking this drug have normal to low serum testosterone concentrations, which is consistent with the suppressive effect of danazol on ovarian function.
